C4 Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	58.81	55.5	126.59	29.75	76.12	181.73
Short-Term Investments	133.08	189.41	127.09	246.4	233.16	189.96
Cash & Short-Term Investments	191.88	244.9	253.68	276.15	309.28	371.69
Cash Growth	-24.94%	-3.46%	-8.14%	-10.71%	-16.79%	310.48%
Receivables	6.54	3.1	11.8	1.47	5.72	4.48
Prepaid Expenses	8.44	9.76	5.71	9.93	10.69	4.84
Total Current Assets	206.86	257.77	271.19	287.56	325.69	381.01
Property, Plant & Equipment	47.1	63.38	71.09	77.52	35.05	16.55
Long-Term Investments	7.88	22.36	28.01	60.96	142.2	-
Other Long-Term Assets	3.65	6.1	6.17	4.81	3.82	2.58
Total Assets	265.49	349.6	376.45	430.84	506.77	400.14
Accounts Payable	1.33	1.33	1.45	1.17	4.51	5.68
Accrued Expenses	9.52	17.49	15.49	16.66	13.19	9.06
Current Portion of Long-Term Debt	-	-	-	2.29	-	-
Current Portion of Leases	6.22	5.77	5.22	4.7	1.33	1.04
Current Unearned Revenue	17.13	18.71	15.47	16.62	31.8	27.6
Other Current Liabilities	1.75	1.87	5.14	3.11	0.41	0.47
Total Current Liabilities	35.95	45.18	42.77	44.55	51.25	43.85
Long-Term Debt	-	-	-	9.2	10.77	10.05
Long-Term Leases	55.25	59.98	65.76	70.97	30.78	11.83
Long-Term Unearned Revenue	19.89	28.46	21.81	16.9	24.37	53.62
Total Liabilities	111.08	133.62	130.34	141.61	117.16	119.35
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	872.52	849.63	774.62	689.26	658.09	464.6
Retained Earnings	-718.21	-633.7	-528.38	-395.89	-267.72	-183.82
Comprehensive Income & Other	0.09	0.05	-0.13	-4.14	-0.78	0.01
Total Common Equity	154.41	215.99	246.11	289.23	389.61	280.79
Shareholders' Equity	154.41	215.99	246.11	289.23	389.61	280.79
Total Liabilities & Equity	265.49	349.6	376.45	430.84	506.77	400.14
Total Debt	61.46	65.76	70.98	87.15	42.88	22.92
Net Cash (Debt)	138.3	201.51	210.71	249.96	408.6	348.77
Net Cash Growth	-36.36%	-4.37%	-15.70%	-38.82%	17.16%	354.13%
Net Cash Per Share	1.94	2.90	4.24	5.12	8.87	30.67
Filing Date Shares Outstanding	96.91	70.99	68.6	49.05	48.74	43.12
Total Common Shares Outstanding	74.17	70.63	60.47	48.97	48.69	43.06
Working Capital	170.92	212.59	228.42	243.01	274.44	337.16
Book Value Per Share	2.08	3.06	4.07	5.91	8.00	6.52
Tangible Book Value	154.41	215.99	246.11	289.23	389.61	280.79
Tangible Book Value Per Share	2.08	3.06	4.07	5.91	8.00	6.52
Machinery	10.99	10.37	10.18	10.66	9.48	8.41
Construction In Progress	-	-	-	0.18	-	-
Leasehold Improvements	4.55	4.71	4.71	4.68	0.54	0.54

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q